Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This paper updates the results of the clinical trial to examine the efficacy of exogenous leukocyte interferon therapy as adjuvant treatment for osteosarcoma. So far the incidence of metastases is lower and the survival rate is better for the interferon-treated group than for the concurrent control group. The number of treated patients is too small at present to allow proper statistical calculations to be made.
 ...
PMID:Adjuvant interferon treatment of human osteosarcoma. 617

After infection with Sendai virus or Newcastle disease virus (NDV) strain F, human osteosarcoma MG63 cells produced large amounts of interferon-beta. Both interferon production and overall protein synthesis were strongly inhibited by hypertonic salt. Interferon mRNA synthesis, however, was little affected by hypertonic salt up to twice normal salt concentrations, although cellular RNA synthesis was inhibited under these conditions. The results are compared to those obtained with polyriboinosinic acid: polyribocytidylic acid copolymer [poly(rI) . poly(rC)] inductions of MG63 cells.
 ...
PMID:The effect of hypertonic salt on interferon and interferon mRNA synthesis in human MG63 cells. 617 28

In eight patients with osteosarcoma we conducted a controlled tolerance study with human lymphoblast interferon. Interferon was applied for 12 months and the control period after stopping interferon has lasted 12-42 months up to now. 4 out of 8 patients who received interferon did not show any adverse reaction concerning clinical and laboratory tests during the course of a 1-year application and during the follow-up period, resp. Only reversible thrombopenias and an increase in the alpha 2-globulins fraction were observed in the interferon and in the control group, resp. All of the 8 patients have up to now survived tumor-free.
 ...
PMID:[Interferon/Controlled study in 3-year survival of patients with osteosarcoma (author's transl)]. 617 24

Since 1972, all cases of osteosarcoma (48 patients) at the Karolinska Hospital in Stockholm have been treated by leukocyte interferon. It has been administered by intra-muscular injections with a dosage of 3 million standard interferon units daily for one month and thereafter 3 times weekly for a further 17 months. Thirty-two patients were subjected to amputation or disarticulation, but in 16 cases local surgery has been resorted to and the defect after tumour resection has been replaced by autogenous bone grafting or endoprostheses. In 5 of 16 locally treated cases, local recurrence occurred and amputation was performed. Four of the patients later on succumbed from metastases. The selection of cases which can be treated by local resection is difficult. In the present series, the rate of survival was 58% after 5 years. Before 1972 (historical group) the survival rate was 14%. The corresponding - 5 - year survival figure for the contemporary group treated without interferon is 33%. Although the 58% survival rate seems to represent an effect of interferon on osteosarcoma, no statistically significant conclusions can be drawn.
 ...
PMID:Treatment of osteosarcoma by interferon and differentiated surgery. 618 17

The antitumor activity of interferon against Dunn osteogenic sarcoma in C3H/HeN mice was studied. The administration of murine interferon prolonged the mean survival days, and reduced pulmonary metastases after the excision of the primary tumor. The administration of interferon augmented natural killer cell activity in vitro, and eliminated tumor cells from the lung rapidly. This rapid cytolysis of tumor cells occurring in vivo correlated well with NK activity in the spleens measured in vitro. These findings suggest that NK cells augmented by interferon have a major effect during the early period of pulmonary metastases.
 ...
PMID:The antitumor effect of interferon against murine osteogenic sarcoma. 618 27

Since 1970, we have carried out cancer chemotherapy and immunotherapy in cooperation with Japanese scientists, particularly Prof. H. Umezawa, who has generously supplied bleomycin, peplomycin, acalcinomycin A (ACM), THP-adriamycin (THP), neothramycin and bestatin. Malignant tumors curable by pharmacotherapy are polycythemia vera (CR 100%), acute lymphoid leukemia (ALL) (CR 80%), Burkitt tumor (CR 80 or 50%), Hodgkin disease (CR 80%), chorioepithelioma (CR 80%), testicular cancer (CR 80%), ovary cancer of children (CR 80%), Wilms renal cancer (CR 60%), rhabdomyosarcoma (CR 75%), osteosarcoma (CR 60%), Ewing tumor (CR 60%), brain tumor of children (CR greater than 50%), testicular embryonal cancer of children (CR greater than 50%), acute myeloid leukemia (AML) (CR 50%), non-Hodgkin lymphoma (NHL) (CR 50%), ovary cancer of adults (CR 40%), small cell lung cancer (CR 20%) and breast cancer. Our experimental and/or clinical experience with ACM, THP, methoxy-9-ellipticine lactate, navelbine, 4-demethyl-epipodophyllotoxin-beta-d-ethyledene glucoside, bestatin and interferon is presented. ACM is effective against AML, ALL, NHL, Burkitt tumor, breast cancer. We have comparatively investigated cardiac and dermal toxicity of 12 kinds of anthracycline antibiotics and mitoxantrone, using golden hamsters. Of the drugs examined, ACM, THP, AD-32 and AD-143 cause much less cardiomyopathy and alopecia than the other agents. The results have been confirmed by electron microscopic studies. Bestatin is an immunorestorator, which recovers immunological functions decreased in aged animals. We hope that cancer chemotherapy and immunotherapy will progress in future and contribute to cure of neoplasms. Japanese scientists have been making a great contribution in the field of cancer pharmacotherapy, and we are eager to cooperate with Japanese scientists in cancer treatment studies.
 ...
PMID:[Japanese-French cooperation in tumor pharmacotherapy: 1970-1990]. 619 71

In a cooperative adjuvant chemotherapy study of osteosarcoma (COSS-80), 192 patients were registered from December 1979 to March 1982. Forty-one patients have been excluded from study because of their nonadjuvant situation, therapy-limiting clinical conditions, or inadequate diagnosis. One hundred and fifty-one patients have been randomized to receive either the drug combination bleomycin + cyclophosphamide + dactinomycin (BCD) or cisplatinum (CPL) within a course of sequential multidrug chemotherapy including adriamycin (ADR) and high dose methotrexate (HDMTX). After exclusion of 51 patients with some deviation in history and/or management 100 selected patients were randomized once more to receive in addition or not fibroblast interferon after preoperative chemotherapy and surgical removal of the primary tumor. Patients were stratified for age and sex and for site and extension of tumor as well in both randomizations. Median follow up is now 12 (1-16) months. The expected 2-year disease free survival (DFS) rate of the total doubly randomized group is 78% and of the single randomized group 76%. No difference could be discerned between recombined groups receiving BCD vs CPL or interferon vs no interferon. The effect of preoperative chemotherapy on the tumor was evaluated clinically and by histopathologic grading; 66/85 (78%) patients were judged clinically as responders with pathohistologic verification of this finding in 71% of these cases. No adverse effect arose from delaying definite surgery for preoperative chemotherapy, but initial application of chemotherapy as well as planning, preparing, and performing of the surgical procedure have been facilitated. The majority of patients received some kind of limb-salvage treatment without local recurrences so far. A statistically insignificant but intriguing tendency for a slightly higher incidence of pulmonary metastases after resection as opposed to amputation could be detected. Similar to observations in the previous study COSS-77.
 ...
PMID:Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study. 619 23

To study the effect of interferon (IFN) on bone induction and new bone formation, heterotopic bone was induced by implanting pieces of demineralized bone matrix in soft tissue of mice. Mouse IFN was given as daily subcutaneous injections of 2 X 10(5) IU/mouse. Treatment was started one week before bone matrix implantation and continued until sacrifice. As a measure of chondrogenesis in the implants short-term incorporation of 35sulphur administered 11 days after implantation was measured. The amount of mineralized tissue formed in connection with the implant was estimated by 45calcium incorporation 20 days after implantation. There was no indication of a negative effect of IFN on bone induction, new bone formation, or metabolism of orthotopic bone. This is in agreement with our findings in the clinical use of IFN after reconstructive surgery in osteosarcoma.
 ...
PMID:Effect of interferon on heterotopic new bone formation in mice. 620 70

Satisfactory experimental models for preclinical prediction in cancerology must answer the following criteria: reproducibility of the method used for inducing tumors; clinical, pathological and kinetic similarity with the corresponding human tumors. We have developed a model of osteosarcoma locally induced by insoluble radioactive cerium chloride (144Ce CI3) in Sprague Dawley rats. This method yields over 80% of bone tumors at the injection site, of which approximately half are histologically similar to human tumors. These tumors double their volume fairly slowly (in approximately 20 days); lung metastases occur both early and frequently (80% of animals). A transplantable tumor was developed from an induced osteosarcoma and adapted to the Curie strain. Transplantation in the bone, next to the bone, or under the skin is followed by widespread metastatic dissemination. The kinetics and histological features of the primary tumor are maintained. Tumor 85 strontium uptake is similar to that seen in human osteosarcomas. These new models of osteosarcomas are being used for evaluating new cancer chemotherapeutic agents and interferon, etc.
 ...
PMID:[An experimental model of osteosarcomas in rats ]. 628 49

We have demonstrated that normal human bone marrow stromal cells can be induced to produce high levels of beta-interferon (IFN). One of three randomly selected human stromal cell lines produced beta-IFN in similar amounts to one of the best beta-IFN producer cell lines produced beta-IFN in similar amounts to one of the best beta-IFN producer cell lines (MG-63 osteosarcoma cells). The marrow stromal cell lines did not produce gamma-IFN, though a low level of alpha-IFN was apparently produced. The stromal cell lines differ from usual producer cell lines in that they can be subcultured for a much longer growth period and also maintain the ability to producer IFN. The cells are karyotypically normal and are not virus transformed. Such cell lines may be useful in the production of human IFN as well as allowing studies on the role of IFN in stromal cell-haemopoietic cell interactions.
 ...
PMID:Interferon production by human marrow stromal cells. 630 91


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>